HomeCompareFRTAF vs ABBV

FRTAF vs ABBV: Dividend Comparison 2026

FRTAF yields 8.23% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRTAF wins by $122881.40M in total portfolio value
10 years
FRTAF
FRTAF
● Live price
8.23%
Share price
$29.77
Annual div
$2.45
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$122881.50M
Annual income
$120,078,547,917.17
Full FRTAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FRTAF vs ABBV

📍 FRTAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRTAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRTAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRTAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRTAF
Annual income on $10K today (after 15% tax)
$699.53/yr
After 10yr DRIP, annual income (after tax)
$102,066,765,729.59/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FRTAF beats the other by $102,066,744,673.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRTAF + ABBV for your $10,000?

FRTAF: 50%ABBV: 50%
100% ABBV50/50100% FRTAF
Portfolio after 10yr
$61440.80M
Annual income
$60,039,286,344.47/yr
Blended yield
97.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FRTAF
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
2.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRTAF buys
0
ABBV buys
0
No recent congressional trades found for FRTAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRTAFABBV
Forward yield8.23%3.06%
Annual dividend / share$2.45$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$122881.50M$102.3K
Annual income after 10y$120,078,547,917.17$24,771.77
Total dividends collected$122690.37M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: FRTAF vs ABBV ($10,000, DRIP)

YearFRTAF PortfolioFRTAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,346$1,645.95$11,550$430.00+$796.00FRTAF
2$17,008$3,798.29$13,472$627.96+$3.5KFRTAF
3$27,980$9,780.81$15,906$926.08+$12.1KFRTAF
4$60,013$30,074.71$19,071$1,382.55+$40.9KFRTAF
5$184,787$120,572.58$23,302$2,095.81+$161.5KFRTAF
6$891,657$693,935.22$29,150$3,237.93+$862.5KFRTAF
7$7,212,891$6,258,818.32$37,536$5,121.41+$7.18MFRTAF
8$102,352,438$94,634,644.49$50,079$8,338.38+$102.30MFRTAF
9$2,619,583,343$2,510,066,234.28$69,753$14,065.80+$2619.51MFRTAF
10$122,881,502,094$120,078,547,917.17$102,337$24,771.77+$122881.40MFRTAF

FRTAF vs ABBV: Complete Analysis 2026

FRTAFStock

freenet AG provides telecommunications, radio and multimedia, mobile communications, mobile Internet, and digital lifestyle services in Germany. It provides a portfolio of services and products primarily in the areas of mobile voice and data services. The Mobile Communications segment offers mobile communications services, such as marketing of mobile communications services, which include voice and data services from the mobile communications network operators; sells and distributes mobile communications devices, as well as offers additional services for mobile data communications and digital lifestyle; and planning, construction, installation, and maintenance services for WiFi networks. The TV and Media segment provides services to end users in the field of DVB-T2 and IPTV; and planning, project management, installation, operation, service, and marketing services for broadcast-related solutions for business clients in the radio and media sectors. The Other/Holding segment offers portal services, such as e-commerce/advertising services; payment services; various digital products and entertainment formats for downloading and displaying, as well as use on mobile devices; communication development solutions, IT solutions, and other services; and voice and data services. The company provides its services under the mobilcom debitel, GRAVIS, MEDIA BROADCAST, klarmobile.de, freenet ENERGY, vitrado.de, FUNK, freenet BASICS, freenet MOBILE, freenet VIDEO, freenet.de, freenet FLEX, freenet TV, waipu.tv, CARMADA, The Cloud, and freenet Business brands. It operates approximately 520 mobilcom-debitel shops and 40 GRAVIS stores. The company sells its products through approximately 400 electronics stores, as well as online platforms. freenet AG was founded in 2005 and is headquartered in Büdelsdorf, Germany.

Full FRTAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FRTAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRTAF vs SCHDFRTAF vs JEPIFRTAF vs OFRTAF vs KOFRTAF vs MAINFRTAF vs JNJFRTAF vs MRKFRTAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.